^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD4 expression

i
Other names: CD4, CD4 Molecule, T-Cell Surface Glycoprotein CD4, T-Cell Surface Antigen T4/Leu-3, CD4 Antigen (P55), CD4 Receptor, CD4 Antigen, CD4mut
Entrez ID:
Related biomarkers:
1d
Antiviral immune response against HTLV-1 invalidates T-SPOT.TB® results in patients with HTLV-1-positive rheumatic diseases. (PubMed, Front Immunol)
Moreover, HTLV-1-associated immune reactions due to contact between these cells may be unlikely to occur in QFT using whole blood. Therefore, our results reveal the superiority of QFT over T-SPOT.TB® as a screening test for LTBI in HTLV-1-positive patients with RD.
Journal
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
|
CD4 expression
24d
Bioinformatic analysis of neuropeptide related genes in patients diagnosed with invasive breast carcinoma. (PubMed, Comput Biol Med)
In BC patients, increases in HCRTR2 and PPY gene expressions could be considered as positive prognostic factors. Decreases in HCRTR1 and NPY4R (PPYR1) gene expressions could be considered as negative prognostic factors. Decreased expression of PTPN11 gene may have a positive prognostic factor. Changes in existing genes are likely to be both a biomarker and therapeutic target for BC. However, experimental and clinical studies are needed to elucidate the mechanisms underlying these neuropeptide receptors in terms of breast carcinogenesis.
Journal • BRCA Biomarker
|
CD8 (cluster of differentiation 8) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • BRCA (Breast cancer early onset) • CD4 (CD4 Molecule)
|
CD8 expression • CD4 expression
27d
Prostate cancer cell-derived exosomes ZNF667-AS1 reduces TGFBR1 mRNA stability to inhibit Treg expansion and DTX resistance by binding to U2AF1. (PubMed, Mol Med)
ZNF667-AS1 suppressed cell growth of PC cells, tumor growth of mice and DTX resistance to PC cells and exogenously high ZNF667-AS1 expression in tumor-derived exosomes destabilized TGFBR1 mRNA and reduce TGFBR1 expression through interacting with U2AF1, thus resulting in attenuated Treg expansion, which was related to DTX resistance.
Journal
|
IL2RA (Interleukin 2 receptor, alpha) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
|
CD4 expression
|
docetaxel
1m
Immunological responses to brain metastasis stereotactic radiosurgery in patient-matched longitudinal blood and tumour samples. (PubMed, Clin Transl Radiat Oncol)
A sizeable proportion of T cell clonotypes were retained post-SRS, and four clones demonstrated significant, non-stochastic expansion. Systemic and local immunological changes in this homogenous patient cohort suggest that SRS may facilitate MHC-II-restricted T cell priming responses involving the monocyte-macrophage lineage and CD4+ T cells, which should be further explored.
Journal • PD(L)-1 Biomarker • IO biomarker • Surgery
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule)
|
PD-L1 expression • HER-2 amplification • PD-1 expression • HER-2 amplification + PD-L1 expression • MHC-II expression • CD4 expression
1m
Clinical prognosticators and targets in the immune microenvironment of intrahepatic cholangiocarcinoma. (PubMed, Oncoimmunology)
These results highlight the importance of CD4+ T cells in immune response against ICC. Secondly, a subset of tumors with "hot" TIME represents potential candidates for ICI, while stimulation of STAT1 pathway could be a potential target to turn "cold" into "hot" TIME in ICC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • FOXP3 (Forkhead Box P3)
|
PD-L1 expression • CD4 expression • FOXP3 expression
2ms
Decreased Expression of CD247 and CD4 Immune Marker Predicts Poor Prognosis in Triple Negative Breast Cancer. (PubMed, Asian Pac J Cancer Prev)
We've concluded that low levels of CD247 and CD4 may stop immune cells from entering the area around the tumor, which stops cancer cells from being killed and gives the patient a bad outlook. These findings suggest that CD247 and CD4 may be useful biomarkers or as a target to understand the progression of TNBC. Our findings also suggest that CD247 and CD4 targeted therapeutics should be explored in detail, and could be a potentially used as atreatment strategy for TNBC.
Journal
|
CD8 (cluster of differentiation 8) • CD47 (CD47 Molecule)
|
CD4 expression
2ms
c-CBL/LCK/c-JUN/ETS1/CD28 axis restrains childhood asthma by suppressing Th2 differentiation. (PubMed, Mol Med)
c-CBL alleviated asthma and suppressed Th2 differentiation by facilitating LCK ubiquitination, interrupting c-JUN activation and CD28 expression in vivo and in vitro. c-CBL/LCK/c-JUN/ETS1/CD28 axis was partially involved in childhood asthma, and may provide novel insights for clinical treatment for asthma.
Journal
|
CBL (Cbl proto-oncogene) • CD4 (CD4 Molecule) • CD28 (CD28 Molecule) • ETS1 (ETS Proto-Oncogene 1) • LCK (LCK Proto-Oncogene, Src Family Tyrosine Kinase) • JUN (Jun proto-oncogene)
|
CD28 expression • CD4 expression • LCK overexpression
2ms
Expression and diagnostic value of lymphocyte subsets and activation status in non-Hodgkin's lymphoma-associated hemophagocytic lymphohistiocytosis (PubMed, Zhonghua Xue Ye Xue Za Zhi)
Specifically, absolute counts of NK cells ≤72.0 cells/μl, CD4(+)CD28(+)/CD4(+) T >94.2%, and CD8(+)CD28(+)/CD8(+) T >38.4% were identified as risk factors for predicting the development of NHL-HLH patients. This will assist in early clinical diagnosis and treatment.
Retrospective data • Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CD38 (CD38 Molecule) • CD4 (CD4 Molecule) • CD28 (CD28 Molecule)
|
CD38 expression • CD8 expression • CD28 expression • CD4 expression
2ms
Low CD86 expression is a predictive biomarker for clinical response to the therapeutic HPV vaccine, IGMKK16E7: Results of a post-hoc analysis. (PubMed, JNCI Cancer Spectr)
Low expression of CD86 in exfoliated cervical cells can be used as a pre-treatment biomarker to predict histological CR after IGMKK16E7 use.
Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3) • ITGAE (Integrin Subunit Alpha E) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)
|
CTLA4 expression • CD4 expression • FOXP3 expression
2ms
Unveiling the Rarity: CD20 Expression in Mycosis Fungoides and Its Clinical Significance. (PubMed, Am J Dermatopathol)
Further investigation and documentation of similar cases is imperative to elucidate the clinical features, prognosis, and optimal therapeutic strategies. The long-term prognosis and outcomes in patients with hypopigmented MF and CD20 positivity remain ambiguous, underscoring the necessity for continued research and scrutiny of analogous cases.
Journal
|
CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD7 (CD7 Molecule)
|
CD20 positive • CD20 expression • CD8 expression • CD4 expression
2ms
Identification of a transcription factor network regulating anti-TNF mediated IL10 expression in human CD4+ T cells. (PubMed, Discov Immunol)
We identified seven transcription factor candidates for the anti-TNF mediated regulation of IL-10, which were either differentially expressed or whose locus was differentially accessible upon anti-TNF treatment. Correlation analysis between the expression of these transcription factors and IL10 suggests a role for MAF, PRDM1, and/or EOMES in regulating IL10 expression in CD4+ T cells upon anti-TNF treatment.
Journal
|
IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • PRDM1 (PR/SET Domain 1) • IL22 (Interleukin 22)
|
CD4 expression
2ms
Efficient Capture and Traceless Release of Functional CD8+ T Cells with a Microfluidic Chip for Enhanced In Vitro and In Vivo CD4-CAR Transduction. (PubMed, Anal Chem)
Meanwhile, anti-CD4 CD8-CAR T cells significantly inhibited tumor growth in vivo. In conclusion, the presented microfluidic chip offers a cost-effective and high-purity approach for CD8+ T cell separation, enhancing CD4-CAR transduction and achieving efficient antitumor capability both in vitro and in vivo.
Preclinical • Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
CD4 expression
6ms
FaCIL-2: Low-dose Interleukin-2 in Women With Unexplained Miscarriages (clinicaltrials.gov)
P1/2, N=18, Completed, Assistance Publique - Hôpitaux de Paris | Active, not recruiting --> Completed
Trial completion
|
CD4 (CD4 Molecule) • IL2 (Interleukin 2)
|
CD4 expression
6ms
Type B thymomas in patients with myasthenia gravis display a distinctive pattern of αβ TCR and IL-7 receptor α expression on CD4+CD8+ thymocytes. (PubMed, Autoimmunity)
We observed that the percentage of Helios-positive CD4SP T cells was greater in MG (-) than in MG (+) thymomas. Thus, the differentially regulated selection process of CD4+CD8+ thymocytes, which involves TCR and IL-7/IL-7Rα signaling, is associated with the presence of MG in type B thymomas.
Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • IL7 (Interleukin 7)
|
CD8 expression • CD4 expression
6ms
Correlation of gasdermin B staining patterns with prognosis, progression, and immune response in colorectal cancer. (PubMed, BMC Cancer)
The GSDMB staining patterns are linked to its role in cancer progression, the immune microenvironment, systemic inflammatory response, chemotherapeutic efficacy, and prognosis. Colorectal cancer cells with high GSDMB expression are more sensitive to 5-fluorouracil. However, GSDMB expression in immune cells has different effects on cancer progression from that in cancer cells.
Journal
|
CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • S100A8 (S100 Calcium Binding Protein A8) • CD68 (CD68 Molecule) • GSDMB (Gasdermin B)
|
CD4 expression • GSDMB expression
|
5-fluorouracil
7ms
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study). (PubMed, Future Oncol)
Introduction: The Meet-URO 18 study is a multicentric study of patients with metastatic renal cell carcinoma receiving nivolumab in the second-line and beyond, categorized as responders (progression-free survival ≥ 12 months) and non-responders (progression-free survival < 3 months)...Responders' tumor tissue (n = 90; 55.9%) was associated with lower CD4 expression (p = 0.014), higher CD56 expression (p = 0.046) and higher CD8/CD4 ratio (p = 0.030). Expert opinion/commentary: The present work suggests the regulatory role of a subpopulation of T cells on antitumor response and identifies CD56 as a putative biomarker of immunotherapy efficacy.
Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • mTOR (Mechanistic target of rapamycin kinase) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD68 (CD68 Molecule) • FUT4 (Fucosyltransferase 4)
|
PD-L1 expression • NCAM1 expression • CD4 expression • CD4 underexpression • NCAM1 overexpression
|
Opdivo (nivolumab)
7ms
N6-Methyladenosine Promotes TNF mRNA Degradation In CD4+ T Lymphocytes. (PubMed, J Leukoc Biol)
Furthermore, we identified that the m6A reader protein YT521-B homology domain family-2 (YTHDF2) binds m6A-methylated TNF mRNA, and promotes its degradation. Taken together, this study demonstrates that TNF expression in CD4+ T lymphocytes is regulated via m6A and YTHDF2, thereby providing novel insight into the regulation of T cell effector functions.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2)
|
CD4 expression
7ms
Inflammatory pathways confer resistance to chemoradiotherapy in anal squamous cell carcinoma. (PubMed, NPJ Precis Oncol)
Inflammatory pathways in tissue in line with elevated levels of regulatory T-cells and CXCL2 in peripheral blood are associated with resistance to CRT. To counteract this resistance mechanism, the RADIANCE randomized phase-2 trial currently tests the addition of the immune checkpoint inhibitor durvalumab to standard CRT in locally advanced ASCC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IFNA1 (Interferon Alpha 1)
|
PD-L1 expression • CD4 expression
|
Imfinzi (durvalumab)
7ms
T-bet Regulates Ion Channels and Transporters and Induces Apoptosis in Intestinal Epithelial Cells. (PubMed, Adv Sci (Weinh))
Herein, a Tet-O-T-bet transgenic mouse strain is generated for doxycycline-inducible T-bet expression in adult animals...Furthermore, ectopic T-bet expression enhances gut epithelial cell apoptosis and markedly suppresses colon cancer development in xenograft models. Collectively, the findings unveil a previously unrecognized role of T-bet in intestinal epithelial cells for inducing apoptosis, diarrhea, and local inflammation, thus implicating its potential as a therapeutic target for the treatment of cancer and inflammatory diseases.
Journal
|
CD4 (CD4 Molecule) • TBX21 (T-Box Transcription Factor 21)
|
CD4 expression • CD4 overexpression
7ms
The CD318/CD6 axis limits type 1 diabetes islet autoantigen-specific human T cell activation. (PubMed, J Autoimmun)
Strikingly, CD318+ DCs suppressed the proliferation of autoreactive T cells specific for GAD65, a well-known targeted self-antigen in Type 1 Diabetes (T1D). Our study provides new insight into the role of the CD318/CD6 axis in the immunopathogenesis of inflammation, suggesting a novel immunoregulatory role of CD318 in T cell-mediated autoimmune diseases and identifying a potential novel immune checkpoint inhibitor as a target for intervention in T1D which is an unmet therapeutic need.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • CDCP1 (CUB Domain Containing Protein 1)
|
CD8 expression • CD4 expression
7ms
Dual molecule targeting HDAC6 leads to intratumoral CD4+ cytotoxic lymphocytes recruitment through MHC-II upregulation on lung cancer cells. (PubMed, J Immunother Cancer)
Collectively, our findings shed light on the discovery of a new multitarget inhibitor able to induce ICD and MHC-II upregulation in TC-1 tumor cell. These two processes participate in enhancing a specific CD4+ cytotoxic T cell-mediated antitumor response in vivo in our model of lung cancer. This breakthrough suggests the potential of QAPHA as a promising agent for cancer treatment.
Journal • IO biomarker
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD4 (CD4 Molecule) • CALR (Calreticulin) • CRTAM (Cytotoxic And Regulatory T Cell Molecule) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • NKG2D (killer cell lectin like receptor K1)
|
MHC-II expression • CD4 expression
7ms
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=55, Terminated, Fred Hutchinson Cancer Center | Active, not recruiting --> Terminated; Terminated due to slow enrollment and end of funding
Trial termination • CAR T-Cell Therapy
|
BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • CD4 (CD4 Molecule) • SELL (Selectin L)
|
CD19 positive • CD8 expression • CD19 expression • BCL6 rearrangement • BCL2 rearrangement • CD20 negative • CD4 expression
|
cyclophosphamide • fludarabine IV • JCAR014
8ms
Characterization of atypical T cells generated during ex vivo expansion process for T cell-based adoptive immunotherapy. (PubMed, Front Immunol)
Both CD4+ and CD8+ T cell subsets, transduced with HPV16-E7 specific transgenic TCR, demonstrated cytotoxic features after exposure to HPV-16 E7-derived antigen. Ultimately, the presence of such atypical T cells, either mismatched MHC II-restricted TCR/CD8+ T cells or cytotoxic CD4+ T cells, is likely to influence the fate of patient-infused T cell product and would need further investigation.
Preclinical • Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • IL15 (Interleukin 15) • IL7 (Interleukin 7)
|
CD8 expression • CD4 expression
8ms
Exploring the clinical significance of IL-38 correlation with PD-1, CTLA-4, and FOXP3 in colorectal cancer draining lymph nodes. (PubMed, Front Immunol)
Our findings demonstrate that IL-38 expression in colorectal regional nodes from CRC patients is inversely correlated with PD-1/PD-L1 but positively correlated with infiltrating CD4+ or CD8+ lymphocytes. The combined assessment of IL-38 and PD-1 expression in colorectal regional nodes emerges as a promising biomarker for predicting the prognosis of CRC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
|
PD-1 expression • CD8 expression • CD4 expression • PD-1 underexpression
8ms
FaCIL-2: Low-dose Interleukin-2 in Women With Unexplained Miscarriages (clinicaltrials.gov)
P1/2, N=18, Active, not recruiting, Assistance Publique - Hôpitaux de Paris | Trial primary completion date: Feb 2024 --> Jul 2023 | Trial completion date: Feb 2025 --> Apr 2024
Trial completion date • Trial primary completion date
|
CD4 (CD4 Molecule) • IL2 (Interleukin 2)
|
CD4 expression
8ms
CKLF instigates a "cold" microenvironment to promote MYCN-mediated tumor aggressiveness. (PubMed, Sci Adv)
Genetic depletion of CD4+ T regulatory cells abolishes the immunorestrictive and protumorigenic effects of CKLF. Our work supports that disrupting CKLF-mediated cross-talk between tumor and CD4+ suppressor cells represents a promising immunotherapeutic approach to battling MYCN-driven tumors.
Journal
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CCR4 (C-C Motif Chemokine Receptor 4) • CD4 (CD4 Molecule)
|
CD4 expression
8ms
Journal
|
CD4 (CD4 Molecule)
|
CD4 expression
8ms
Variation of peripheral blood-based biomarkers for response of anti-PD-1 immunotherapy in non-small-cell lung cancer. (PubMed, Clin Transl Oncol)
Our research has yielded encouraging results in identifying a correlation between immunotherapy's response and clinical characteristics, peripheral immune cell subsets, and biochemical and immunological biomarkers. The screened hematological detection panel could be used to forecast an NSCLC patient's response to anti-PD-1 immunotherapy with an accuracy rate of 76.3%, which could help customize suitable therapeutic decision-making.
Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
CD8 expression • CD4 expression
9ms
Predicting the mechanism of action of YQYYJD prescription in the treatment of non-small cell lung cancer using transcriptomics analysis. (PubMed, J Ethnopharmacol)
YQ was the key disassembled prescription of YQYYJD, exerting significant antitumor effects and immune regulation effects on NSCLC. It may have relieved T cell exhaustion and regulated the immune microenvironment to exert antitumor effects by changing lung cancer-related targets, pathways, and biological processes.
Journal
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • CASP3 (Caspase 3)
|
CD8 expression • IFNG expression • CD4 expression • IL2 expression
9ms
LAG-3- and CXCR5-expressing CD4 T cells display progenitor-like properties during chronic visceral leishmaniasis. (PubMed, Cell Rep)
The transcriptional repressor B cell lymphoma-6 was partially required for their maintenance. Altogether, we propose that the LAG3+CXCR5+ CD4 T cell subset could play a role in maintaining CD4 T cell responses during persistent infections.
Journal • IO biomarker
|
LAG3 (Lymphocyte Activating 3) • CD4 (CD4 Molecule) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • RAG1 (Recombination Activating 1)
|
LAG3 expression • CD4 expression • CXCR5 expression
9ms
Evaluating CD4 and Foxp3 mRNA Expression in Tissue Specimens of Celiac Disease and Colorectal Cancer Patients. (PubMed, Asian Pac J Cancer Prev)
This study reveals differential expression patterns of CD4 and Foxp3 mRNA in CRC and CD patients. Upregulated CD4 mRNA suggests its potential role in promoting tumor growth, while increased Foxp3 mRNA expression may reflect an immunosuppressive mechanism in CD pathogenesis. These findings provide insights into the molecular and immunological aspects of CRC and CD, warranting further studies for potential therapeutic strategies.
Journal
|
CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
|
CD4 expression • FOXP3 expression
9ms
Kidney double positive T cells have distinct characteristics in normal and diseased kidneys. (PubMed, Sci Rep)
We studied kidney DPT cells in mice at baseline and after ischemia reperfusion (IR) and cisplatin injury...DPT cells constituted a minor population in both normal and cancer portion of human kidneys. In conclusion, DPT cells constitute a small population of mouse and human kidney T cells with distinct inflammatory and metabolic profile at baseline and following kidney injury.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • CCR7 (Chemokine (C-C motif) receptor 7) • IL17A (Interleukin 17A) • CPT1A (Carnitine Palmitoyltransferase 1A) • SLC2A1 (Solute Carrier Family 2 Member 1)
|
PD-1 expression • CD8 expression • CD4 expression
|
cisplatin
9ms
OCA-B/Pou2af1 is sufficient to promote CD4+ T cell memory and prospectively identifies memory precursors. (PubMed, Proc Natl Acad Sci U S A)
We show that early in viral infection, endogenously elevated OCA-B expression prospectively identifies memory precursor cells with increased survival capability and memory recall potential. Cumulatively, the results demonstrate that OCA-B is both necessary and sufficient to promote CD4 T cell memory in vivo and can be used to prospectively identify memory precursor cells.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CD4 (CD4 Molecule) • IL7R (Interleukin 7 Receptor) • SOCS2 (Suppressor Of Cytokine Signaling 2) • GADD45B (Growth Arrest And DNA Damage Inducible Beta) • POU2AF1 (POU Class 2 Homeobox Associating Factor 1) • TCF7 (Transcription Factor 7)
|
BCL2 expression • CD4 expression • SOCS2 expression
9ms
Canine T zone lymphoma is a tumor of mature, previously activated αβ T cells. (PubMed, Vet Immunol Immunopathol)
TZL cells do not proliferate when stimulated through the T cell receptor but will divide when the T cell receptor is bypassed with PMA and ionomycin. The observation that these cells are derived from a mature, previously activated T cell is the first step in understanding the genesis of this unique T cell tumor.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • GATA3 (GATA binding protein 3)
|
CD8 expression • PTPRC expression • CD4 expression
9ms
Profiling Fibroblast Growth Factor Receptor 3 Expression Based on the Immune Microenvironment in Upper Tract Urothelial Carcinoma. (PubMed, Eur Urol Oncol)
Although most patients exhibit a poor response to Pem, individuals with low FGFR3 expression and immune hot status may benefit clinically from Pem treatment.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • FGFR3 (Fibroblast growth factor receptor 3) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • MSR1 (Macrophage Scavenger Receptor 1)
|
FGFR3 mutation • CD8-H • FGFR3 expression • CD4 expression
|
Keytruda (pembrolizumab)
10ms
Development of Innate-Immune-Cell-Based Immunotherapy for Adult T-Cell Leukemia-Lymphoma. (PubMed, Cells)
Anti-CCR4 antibodies enhanced the cytotoxic activity of the γδ T cells and NK cells against HTLV-1-infected CCR4-expressing CD4 T cells in an antibody concentration-dependent manner. Taken together, the adoptive transfer of γδ T cells and NK cells expanded with PTA/IL-2/IL-18 is a promising alternative therapy for ATL.
Journal • Immune cell
|
CCR4 (C-C Motif Chemokine Receptor 4) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL18 (Interleukin 18)
|
CD4 expression
10ms
Single institution study of the immune landscape for canine oral melanoma based on transcriptome analysis of the primary tumor. (PubMed, Front Vet Sci)
This preliminary study reports significant changes in gene expression for oral melanoma between canine patients with localized disease relative to those with metastatic disease. In the future, a more in-depth investigation involving immunohistochemistry analysis and single-cell RNA expression is necessary to confirm our findings.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • BCL2 (B-cell CLL/lymphoma 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • ANXA1 (Annexin A1) • IL18 (Interleukin 18) • TLR4 (Toll Like Receptor 4) • TP63 (Tumor protein 63) • CEACAM1 (CEA Cell Adhesion Molecule 1) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
|
BCL2 expression • TIGIT expression • VEGFA expression • CD4 expression
10ms
IFNγ drives neuroinflammation, demyelination, and neurodegeneration in a mouse model of multiple system atrophy. (PubMed, Acta Neuropathol Commun)
Results from these studies indicate that IFNγ expression from CD4+ T cells drives α-syn-mediated neuroinflammation, demyelination, and neurodegeneration. These results indicate that targeting IFNγ expression may be a potential disease modifying therapeutic strategy for MSA.
Preclinical • Journal
|
IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
|
IFNG expression • CD4 expression
10ms
Role of Inflammatory Markers in Sepsis (clinicaltrials.gov)
P=N/A, N=60, Recruiting, National Cancer Institute, Egypt | Not yet recruiting --> Recruiting
Enrollment open
|
IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • IL17A (Interleukin 17A) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
|
IL2RA expression • CD4 expression
10ms
Targeting TIGIT for cancer immunotherapy: recent advances and future directions. (PubMed, Biomark Res)
Although two clinical studies on advanced lung cancer had positive results, the TIGIT-targeted antibody, tiragolumab, recently failed in two new trials. In this review, we highlight the current developments on TIGIT for cancer immunotherapy and discuss the characteristics and functions of TIGIT.
Review • Journal
|
CD8 (cluster of differentiation 8) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • PVR (PVR Cell Adhesion Molecule)
|
CD8 expression • CD4 expression
|
tiragolumab (RG6058)
10ms
E3 ubiquitin ligase casitas B-lineage lymphoma-b modulates T-cell anergic resistance via phosphoinositide 3-kinase signaling in patients with immune thrombocytopenia. (PubMed, J Thromb Haemost)
CD4 T cells from patients with ITP showed resistance to anergic induction, highly activated phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT) signaling, decreased CBLB expression, and 5' UTR hypermethylation of CBLB. CBLB overexpression in T cells effectively attenuated the elevated p-AKT level and resistance to anergy. Low-dose decitabine treatment led to significantly elevated CBLB expression in CD4 T cells from seven patients showing a partial or complete response. These results indicate that the 5' UTR hypermethylation of CBLB in CD4 T cells induces resistance to T-cell anergy in ITP. Thus, the upregulation of CBLB expression by low-dose decitabine treatment may represent a potential therapeutic approach to ITP.
Journal
|
CD4 (CD4 Molecule) • CBLB (Cbl Proto-Oncogene B)
|
CD4 expression
|
decitabine
11ms
SPP1 is associated with adverse prognosis and predicts immunotherapy efficacy in penile cancer. (PubMed, Hum Genomics)
Our study shows that the SPP1 gene might be an effective biomarker for predicting the prognosis and the efficacy of immunotherapy in PSCC patients.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • SPP1 (Secreted Phosphoprotein 1) • CD4 (CD4 Molecule)
|
PD-L1 expression • CD4 expression • SPP1-L